K
Korea Pharma Co Ltd
KOSDAQ:032300
Korea Pharma Co Ltd
KOSDAQ:032300
Price:
12 720
KRW
Market Closed
Market Cap:
₩138.8B
Income Statement
Earnings Waterfall
Korea Pharma Co Ltd
Korea Pharma Co Ltd
Income Statement
Korea Pharma Co Ltd
Korea Pharma Co Ltd
Currency: KRW
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
335
|
436
|
380
|
368
|
318
|
908
|
1 792
|
2 683
|
3 541
|
3 867
|
3 930
|
4 037
|
4 197
|
2 851
|
2 499
|
2 138
|
2 880
|
0
|
0
|
0
|
|
| Revenue |
53 745
N/A
|
71 510
+33%
|
72 829
+2%
|
74 394
+2%
|
75 089
+1%
|
79 577
+6%
|
80 283
+1%
|
80 353
+0%
|
81 509
+1%
|
81 029
-1%
|
82 782
+2%
|
85 160
+3%
|
84 549
-1%
|
62 671
-26%
|
59 937
-4%
|
59 333
-1%
|
81 277
+37%
|
81 783
+1%
|
85 338
+4%
|
90 112
+6%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(27 586)
|
(37 352)
|
(38 490)
|
(39 818)
|
(40 468)
|
(43 673)
|
(44 480)
|
(44 713)
|
(46 170)
|
(45 603)
|
(46 282)
|
(48 059)
|
(47 046)
|
(34 949)
|
(33 331)
|
(33 427)
|
(46 103)
|
(46 733)
|
(50 735)
|
(55 096)
|
|
| Gross Profit |
26 159
N/A
|
34 157
+31%
|
34 339
+1%
|
34 577
+1%
|
34 620
+0%
|
35 903
+4%
|
35 802
0%
|
35 641
0%
|
35 339
-1%
|
35 427
+0%
|
36 500
+3%
|
37 101
+2%
|
37 503
+1%
|
27 722
-26%
|
26 607
-4%
|
25 906
-3%
|
35 174
+36%
|
35 050
0%
|
34 602
-1%
|
35 016
+1%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(22 022)
|
(29 554)
|
(29 690)
|
(30 279)
|
(30 321)
|
(30 889)
|
(30 380)
|
(29 195)
|
(28 441)
|
(29 240)
|
(30 036)
|
(30 419)
|
(30 720)
|
(22 123)
|
(21 897)
|
(21 743)
|
(29 087)
|
(29 815)
|
(30 668)
|
(31 672)
|
|
| Selling, General & Administrative |
(15 834)
|
(22 213)
|
(22 150)
|
(23 294)
|
(24 261)
|
(24 963)
|
(25 501)
|
(25 231)
|
(25 594)
|
(25 721)
|
(26 543)
|
(26 964)
|
(27 130)
|
(19 492)
|
(18 995)
|
(18 905)
|
(25 398)
|
(26 148)
|
(26 576)
|
(27 327)
|
|
| Research & Development |
(5 478)
|
(6 221)
|
(6 365)
|
(5 838)
|
(4 907)
|
(4 893)
|
(4 276)
|
(3 487)
|
(2 547)
|
(2 452)
|
(2 212)
|
(2 134)
|
(2 114)
|
(1 415)
|
(1 610)
|
(1 627)
|
(2 053)
|
(1 903)
|
(2 204)
|
(2 339)
|
|
| Depreciation & Amortization |
(710)
|
(1 119)
|
(1 175)
|
(1 147)
|
(1 153)
|
(1 033)
|
(901)
|
(967)
|
(1 075)
|
(1 067)
|
(1 281)
|
(1 321)
|
(1 477)
|
(1 216)
|
(1 293)
|
(1 212)
|
(1 636)
|
(1 764)
|
(1 889)
|
(2 005)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
298
|
489
|
775
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
4 137
N/A
|
4 604
+11%
|
4 649
+1%
|
4 298
-8%
|
4 299
+0%
|
5 014
+17%
|
5 422
+8%
|
6 445
+19%
|
6 897
+7%
|
6 187
-10%
|
6 464
+4%
|
6 682
+3%
|
6 783
+2%
|
5 599
-17%
|
4 709
-16%
|
4 163
-12%
|
6 086
+46%
|
5 235
-14%
|
3 934
-25%
|
3 344
-15%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(299)
|
(450)
|
(403)
|
(344)
|
(294)
|
(830)
|
(1 736)
|
(2 993)
|
(3 789)
|
(7 997)
|
(7 539)
|
(7 294)
|
(7 008)
|
(1 637)
|
(758)
|
(378)
|
(3 678)
|
(4 002)
|
(4 599)
|
(5 075)
|
|
| Non-Reccuring Items |
0
|
0
|
(298)
|
(489)
|
(775)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(242)
|
(248)
|
(248)
|
1 476
|
1 439
|
1 445
|
1 443
|
|
| Gain/Loss on Disposition of Assets |
(819)
|
(837)
|
0
|
(188)
|
0
|
5
|
0
|
62
|
81
|
82
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Total Other Income |
349
|
452
|
(4)
|
488
|
493
|
1 019
|
867
|
966
|
847
|
(51)
|
(11)
|
(259)
|
(253)
|
10
|
15
|
21
|
20
|
306
|
300
|
290
|
|
| Pre-Tax Income |
3 368
N/A
|
3 768
+12%
|
3 945
+5%
|
3 765
-5%
|
3 723
-1%
|
5 208
+40%
|
4 554
-13%
|
4 480
-2%
|
4 036
-10%
|
(1 780)
N/A
|
(1 086)
+39%
|
(871)
+20%
|
(478)
+45%
|
3 730
N/A
|
3 719
0%
|
3 559
-4%
|
3 906
+10%
|
2 978
-24%
|
1 082
-64%
|
2
-100%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(727)
|
(609)
|
(647)
|
1 184
|
1 745
|
1 160
|
1 481
|
(107)
|
(487)
|
661
|
(506)
|
(2 159)
|
(1 953)
|
(1 667)
|
11
|
177
|
(114)
|
12
|
367
|
172
|
|
| Income from Continuing Operations |
2 640
|
3 159
|
3 297
|
4 949
|
5 468
|
6 368
|
6 035
|
4 372
|
3 550
|
(1 119)
|
(1 592)
|
(3 030)
|
(2 430)
|
2 063
|
3 730
|
3 736
|
3 792
|
2 990
|
1 448
|
174
|
|
| Net Income (Common) |
2 640
N/A
|
3 159
+20%
|
3 297
+4%
|
4 949
+50%
|
5 468
+10%
|
6 368
+16%
|
6 035
-5%
|
4 372
-28%
|
3 550
-19%
|
(1 119)
N/A
|
(1 592)
-42%
|
(3 030)
-90%
|
(2 430)
+20%
|
2 063
N/A
|
3 730
+81%
|
3 736
+0%
|
3 792
+2%
|
2 990
-21%
|
1 448
-52%
|
174
-88%
|
|
| EPS (Diluted) |
264
N/A
|
315.89
+20%
|
338.45
+7%
|
453.74
+34%
|
501.35
+10%
|
583.89
+16%
|
553.32
-5%
|
400.9
-28%
|
325.46
-19%
|
-103
N/A
|
-145.96
-42%
|
-277.79
-90%
|
-222.8
+20%
|
189.14
N/A
|
342.02
+81%
|
342.5
+0%
|
347.65
+2%
|
274.12
-21%
|
132.81
-52%
|
15.97
-88%
|
|
Switch to:
Switch to:
See Also
Discover More
